Document is current
Any future updates will be listed below
-
Authors
Vincent, Richard
Rapoport, David
Balchandani, Priti
Borrello, Joseph
Schotsaert, Michael
Karlicek, Robert
Laghlali, Gabriel
Warang, Prajakta
Park, Seokchan
Singh, Gagandeep
Morgan, Isabella
Paredes, James
Rathnasinghe, Raveen
Wolf, Jacob
García-Sastre, Adolfo
-
Funding
Funding for this research was provided by:
NIH/NCATS (Grant 5UL1TR001433-05a)
NIH/NIAID (R01AI160706)
NIH/NIDDK (R01DK130425)
CRIPT (Center for Research on Influenza Pathogenesis and Transmission), a NIH NIAID funded Center of Excellence for Influenza Research and Response ((CEIRR, contract number 75N93021C00014),)
Korea Health Industry 914 Development Institute (KHIDI) for research under the Biomedical Global Talent Nurturing Program ((HI22C2101).)
NIAID (contract 75N93019C00046)
- License Information
-
More Information
Article History
Received: 27 June 2024
Accepted: 10 December 2024
First Online: 30 December 2024
Declarations
:
: The A.G.-S laboratory has received research support from GSK, Pfizer, Senhwa Biosciences, Kenall Manufacturing, Blade Therapeutics, Avimex, Johnson & Johnson, Dynavax, 7Hills Pharma, Pharmamar, ImmunityBio, Accurius, Nanocomposix, Hexamer, N-fold LLC, Model Medicines, Atea Pharma, Applied Biological Laboratories and Merck, outside of the reported work. A.G.-S. has consulting agreements for the following companies involving cash and/or stock: Castlevax, Amovir, Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Pagoda, Accurius, Esperovax, Farmak, Applied Biological Laboratories, Pharmamar, CureLab Oncology, CureLab Veterinary, Synairgen, Paratus, Pfizer and Prosetta, outside of the reported work. A.G.-S. has been an invited speaker in meeting events organized by Seqirus, Janssen, Abbott and Astrazeneca. A.G.-S. is inventor on patents and patent applications on the use of antivirals and vaccines for the treatment and prevention of virus infections and cancer, owned by the Icahn School of Medicine at Mount Sinai, New York. The MS laboratory received unrelated research support as sponsored research agreements from ArgenX BV, Phio Pharmaceuticals, 7Hills Pharma LLC and Moderna, Inc. All other authors did not have a competing interest.
